FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension
Edvardas Kaminskas(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Yongcheng Wang(United States Food and Drug Administration), Ann T. Farrell(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research)
Cited by 488
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k